Targeting Angiogenesis in the Treatment of Multiple

ISSN: 2211-5536 (Online)
ISSN: 2211-5528 (Print)

Volume 4, 2 Issues, 2015

Download PDF Flyer

Current Angiogenesis (Discontinued)

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Guo-Chang Fan
Dept. of Pharmacology and Cell Biophysics
University of Cincinnati College of Medicine

View Full Editorial Board

Purchase Articles Order Reprints

Targeting Angiogenesis in the Treatment of Multiple

Current Angiogenesis (Discontinued), 3(1): 39-47.

Author(s): Najib Dally and Elizabeth Eshel.

Affiliation: Hematology Institute, Ziv Medical Center affiliated with the Faculty of Medicine in Zefat, Bar Ilan University, Zefat, Israel.


Multiple Myeloma (MM) remains an incurable disease. Scientific understanding of the biology and influence of the microenvironment in disease progression and outcome has led to treatment improvements by targeting angiogenesis. Reviews of the underlying biology and meta-analyses of the clinical data tend to be mutually exclusive. This minireview highlights important data regarding angiogenesis in MM as well as the drugs currently used to target angiogenesis in its treatment.


Angiogenesis inhibitors, anti angiogenetic agents, anti-angiogenic effects, immunomodulation, multiple myeloma.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 3
Issue Number: 1
First Page: 39
Last Page: 47
Page Count: 9
DOI: 10.2174/2211552802666140404003016

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science